Provided by Tiger Trade Technology Pte. Ltd.

Dynavax

15.38
+4.2538.19%
Post-market: 15.37-0.0101-0.07%15:17 EST
Volume:30.74M
Turnover:474.10M
Market Cap:1.81B
PE:-42.79
High:15.49
Open:15.49
Low:15.38
Close:11.13
52wk High:15.49
52wk Low:9.20
Shares:117.42M
Float Shares:98.91M
Volume Ratio:27.99
T/O Rate:31.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3595
EPS(LYR):0.2100
ROE:-7.14%
ROA:1.20%
PB:3.38
PE(LYR):73.24

Loading ...

Company Profile

Company Name:
Dynavax
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
405
Office Location:
2100 Powell Street,Suite 720,EmeryVille,California,United States
Zip Code:
94608
Fax:
510 848 1327
Introduction:
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Directors

Name
Position
Ryan Spencer
Chief Executive Officer, Director
Brent MacGregor
Director
Daniel L. Kisner
Director
Elaine Sun
Director
Francis R. Cano
Director
Julie Eastland
Director
Peggy V. Phillips
Director
Peter R. Paradiso
Director
Scott Myers
Director

Shareholders

Name
Position
Ryan Spencer
Chief Executive Officer, Director
David F. Novak
Senior Vice President and Chief Operating Officer
John L. Slebir
Senior Vice President, General Counsel
Kelly MacDonald
Senior Vice President, Chief Financial Officer
Robert Janssen
Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs
Joseph Metzinger
Vice President, Chief Accounting Officer